Blockchain Registration Transaction Record

New Stroke Drug Cuts Recurrence Risk 26% Without Bleeding Danger

New anti-clotting drug asundexian reduces second stroke risk by 26% without increasing bleeding, per American Stroke Association trial. Could transform stroke prevention.

This development matters because stroke remains a leading cause of death and disability worldwide, with survivors facing a 25% chance of experiencing another stroke. Current prevention medications often come with dangerous bleeding risks that limit their effectiveness and duration of use. Asundexian represents a potential breakthrough in balancing stroke prevention with safety, offering hope for millions of stroke survivors who currently face difficult trade-offs between protection from another stroke and risk of serious bleeding complications. If approved, this medication could transform long-term stroke prevention strategies and significantly reduce the burden of recurrent strokes on healthcare systems and families.